Senior Clinical Research Associate
Job Summary
The Sr. CRA is responsible for the execution of key clinical trial activities as delegated by the Clinical Trial lead. Key responsibilities focus on the logistical support for a trial which includes monitoring and management of clinical sites, vendor management and data review, query generation activities on single center or global studies.
Skills & Attributes
Clinical trial experience that includes international Phase 1-3 trials, involving CROs or IST trial led by Investigators, from study set-up through to completion. Experience with Gastrointestinal, hematology and/or orphan drug trials preferred. High level of appreciation and understanding of the feasibility, regulatory and start-up processes, together along with on-site monitoring and site management. Good overall understanding of the major areas within clinical development. Excellent communication and interpersonal skills, along with attention to detail and critical thinking skills. Strong written and spoken English. Ability to collaborate, problem solve and work in a small dynamic organization with minimal supervision, to achieve personal and collective goals.
Experience Required
4+ years as a CRA within Biotech/Pharma, Academia or CRO
Education Required
Bachelor's Degree, preferably in biological science.
Travel Required
Yes, up to 25%
Core Responsibilities
Overall Study Execution
The base pay range for this position at commencement of employment is expected to be between $135K and $150K / year; however, base pay offered may vary depending on multiple individualized factors, including market location, job-related knowledge, skills, and experience.
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. The Company''s proprietary peptide technology platform enables de novo discovery of peptide therapeutics. Two novel peptides derived from Protagonist''s proprietary discovery platform are at or near commercialization. ICOTYDE (icotrokinra) is approved in the U.S. for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. ICOTYDE is the first and only targeted oral peptide that precisely blocks the Interleukin-23 receptor (IL-23R) licensed to Janssen Biotech, Inc.,a Johnson & Johnson company. ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further development and commercialization. An NDA for rusfertide, a first-in-class hepcidin mimetic peptide that is being co-developed with Takeda Pharmaceuticals pursuant to a worldwide license and collaboration agreement entered in 2024, is under priority review with the FDA. Protagonist holds an option to co-commercialize rusfertide in the U.S. through a 50/50 profit and loss share structure or can opt-out of this structure. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets including an oral IL-17 peptide antagonist, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs.
More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company''s website at https://www.protagonist-inc.com.